Cell membrane

Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Retrieved on: 
월요일, 6월 3, 2024
Research, Medical Devices, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, ADP, ASCO, PARP1, Cancer, CEACAM5, Merck Serono, Ovarian cancer, Glioblastoma, ATR, Merck, AACR, Health care, GD2, Patient, Cell, NSCLC, PARP, Society, ADC, DNA, Merck Group, Cell death, Niraparib, Ataxia–telangiectasia, Colorectal cancer, Carcinoma, Clinical trial, Neuroblastoma, Development, Osteosarcoma, Cell membrane, Lung cancer, ATM, DDR, Neoplasm, Part, Antigen, Prevalence, Avelumab, Phase, Pharmaceutical industry

“The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.

Key Points: 
  • “The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.
  • At Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer.
  • Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core.
  • Our vision is to create a world where more cancer patients will become cancer survivors.

Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Retrieved on: 
월요일, 6월 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, ADP, Colorectal cancer, ASCO, PARP1, Cancer, CEACAM5, Ovarian cancer, Glioblastoma, ATR, AACR, Health care, GD2, Patient, Cell, NSCLC, PARP, Society, ADC, DNA, Cell death, Niraparib, Ataxia–telangiectasia, Carcinoma, Clinical trial, Neuroblastoma, Development, Osteosarcoma, Cell membrane, Lung cancer, ATM, Neoplasm, DDR, Part, Antigen, Prevalence, Avelumab, Phase, Pharmaceutical industry

“The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.

Key Points: 
  • “The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.
  • These findings complement data for the first-in-class tuvusertib and lartesertib combination first presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in April.
  • Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core.
  • Our vision is to create a world where more cancer patients will become cancer survivors.

Inipharm to Present Pharmacokinetic Data From a Phase 1 Clinical Trial of INI-822, a Small Molecule Inhibitor of HSD17B13

Retrieved on: 
수요일, 5월 22, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Half-life, Patient, Pharmacokinetics, CDAA, MASH, Plasma, Hepatology, ALT, Liver, Cell membrane, EASL, HSD17B13, Safety, MD, Personal computer, NASH, Rat, Diet, Phospholipid, Alanine transaminase

Inipharm, a biopharmaceutical company focused on developing therapies for fibrotic liver diseases, today announced upcoming presentations of clinical and preclinical data from INI-822, the company’s Phase 1 small molecule inhibitor of HSD17B13, currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH.

Key Points: 
  • Inipharm, a biopharmaceutical company focused on developing therapies for fibrotic liver diseases, today announced upcoming presentations of clinical and preclinical data from INI-822, the company’s Phase 1 small molecule inhibitor of HSD17B13, currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH.
  • The data will be presented at the European Association for the Study of the Liver’s EASL Congress 2024, taking place June 5-8, 2024.
  • In addition, exposures occurred with a half-life that will enable once daily oral dosing in future clinical studies of participants with MASH.
  • These included PCs that have been shown to be elevated in liver biopsies from individuals with the inactive form of the HSD17B13 protein.

Unlocking the Secrets to a Sharper Mind and Healthier Cells

Retrieved on: 
수요일, 4월 17, 2024
Brain, Oxidative stress, Dementia, CDC, Motivation, Cell, Research, History, Nutrient, Cell membrane, Ageing

“Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.

Key Points: 
  • “Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.
  • These products replenish essential nutrients, enhance cellular repair mechanisms, and protect against oxidative stress.
  • They are pivotal for maintaining cell membrane integrity, which is essential for the brain cells that manage information processing and cognitive performance.
  • Return Healthy’s Cell Stabilization Plan is a testament to the company’s commitment to empower individuals to take control of their healthspan with preventive self-care and advanced nutritional support.

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Retrieved on: 
수요일, 3월 20, 2024
Research, Composition, Nerve, Innovation, Psychological trauma, University, P-1, Patent, Stroke, MDXX, TBI, Cell membrane, United States patent law, Traumatic brain injury, OTC, MDMA, Pharmaceutical industry

“The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA.

Key Points: 
  • “The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA.
  • P-1 was submitted to the USPTO through the Patent Prosecution Highway program, allowing for accelerated patent examination.
  • As the molecule is ready for pre-clinical and clinical development, the Company has elected to change its designation to APA-001.
  • In addition there is potential applicability for the fear disorders often discussed in the context of MDMA.”

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

Retrieved on: 
목요일, 3월 21, 2024
B cell, Oncogene, Tissue, Research, Tumor microenvironment, Cell membrane, University, Genomics, Escape Room, Medical imaging

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

Key Points: 
  • PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.
  • These new products expand the breadth of the Xenium single cell spatial analysis menu.
  • The Xenium In Situ Cell Segmentation Kit improves the determination of cell boundaries by using a stain and algorithmic technique developed and validated through custom-trained machine learning models.
  • State-of-the-art, custom-built algorithm: Obtain more accurate cell segmentation with an advanced AI algorithm specifically trained on real-world Xenium cellular and tissue data.

FDA Grants Fast Track Designation to 9MW2821

Retrieved on: 
화요일, 2월 27, 2024
DCR, Carcinoma, Immunotherapy, Cervical cancer, FDA, Food, ESCC, Fast track (FDA), PD-1, Apoptosis, ADC, FTD, UC, Cell membrane, Patient, Esophageal cancer, Fine chemical

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").

Key Points: 
  • SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").
  • 9MW2821 is the world's first Nectin-4-targeting drug to disclose clinical efficacy data for the indication of EC.
  • After injection, 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells.
  • 9MW2821 is also the first to disclose preliminary clinical efficacy data for the indication of CC among drugs with the same target in the world.

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Retrieved on: 
수요일, 12월 20, 2023
Vitamins, Supplements, Neurology, Military, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Defense, Nation, Research, ChromaDex, Gold, Sport, Nobel Prize, NSF, NAD, Cell membrane, Safety, Agonal respiration, Military personnel

In a gesture of gratitude and further support US troops, ChromaDex has launched an exclusive program that offers Tru Niagen products to active and veteran Military Service Members.

Key Points: 
  • In a gesture of gratitude and further support US troops, ChromaDex has launched an exclusive program that offers Tru Niagen products to active and veteran Military Service Members.
  • "We are honored that Tru Niagen will play a role in the health and wellness of our troops,” said Rob Fried, CEO of ChromaDex.
  • For more information about Tru Niagen’s military discount program, please visit https://discover.truniagen.com/military/ .
  • If you are an active or veteran US Military Service Member interested in purchasing Tru Niagen, please email [email protected] for more details.

Kanazawa University research: Sodium channel investigation

Retrieved on: 
수요일, 12월 20, 2023
Noetics, Sodium, Map, Kanazawa University, Wakayama Medical University, The central science, AFM, Arcobacter, B cell, Cell membrane, Observation, Electric potential, Nature, Arcobacter butzleri, Cell, Nature Communications, Neuron, Microscope

KANAZAWA, Japan, Dec. 19, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications a high-speed atomic force microscopy study of the structural dynamics of sodium ion channels in cell membranes.

Key Points: 
  • KANAZAWA, Japan, Dec. 19, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications a high-speed atomic force microscopy study of the structural dynamics of sodium ion channels in cell membranes.
  • An important open question is whether the voltage sensor domains dissociate from the pore domains when the channel closes.
  • One is the sodium channel of a particular bacterium (Arcobacter butzleri), the other two are mutants thereof.
  • In recent years, researchers at Kanazawa University have further developed HS-AFM so that it can be applied for studying biochemical molecules and biomolecular processes in real-time.

Kanazawa University research: Sodium channel investigation

Retrieved on: 
수요일, 12월 20, 2023
Noetics, Sodium, Map, Kanazawa University, Wakayama Medical University, The central science, AFM, Arcobacter, B cell, Cell membrane, Observation, Electric potential, Nature, Arcobacter butzleri, Cell, Nature Communications, Neuron, Microscope

KANAZAWA, Japan, Dec. 19, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications a high-speed atomic force microscopy study of the structural dynamics of sodium ion channels in cell membranes.

Key Points: 
  • KANAZAWA, Japan, Dec. 19, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications a high-speed atomic force microscopy study of the structural dynamics of sodium ion channels in cell membranes.
  • An important open question is whether the voltage sensor domains dissociate from the pore domains when the channel closes.
  • One is the sodium channel of a particular bacterium (Arcobacter butzleri), the other two are mutants thereof.
  • In recent years, researchers at Kanazawa University have further developed HS-AFM so that it can be applied for studying biochemical molecules and biomolecular processes in real-time.